Expert review of pharmacoeconomics & outcomes research

Keyphrases

Publications

volume 24, number 4, 2024

Shih Ping Lai, Shyh-Yau Wang, Agnes Lf Chan, John Hang Leung, Hei-Tung Yip
Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer. Expert review of pharmacoeconomics & outcomes research 24 (4) (2024)
Alberto Raggi, Matilde Leonardi, Paolo Martelletti
A proposal of actions for stakeholders and policy makers to address the global burden of headache disorders by 2030: why is this important for global health? Expert review of pharmacoeconomics & outcomes research 24 (4) (2024)
Muhammad Amir, Ale Zehra, Rabya Munawar, Wajiha Gul, Tehreem Fatima, Younas Khan, Razia Jaffery, Zaheer-Ud-Din Babar
Economic evaluation of clinical pharmacy service using integrated health system in tertiary care hospital. Expert review of pharmacoeconomics & outcomes research 24 (4) (2024)
Bhavik J Pandya, Christopher Young, Elizabeth R Packnett, Bin Xie, Timothy Lillehaugen, Alana Block, Katarzyna Bernacki, Maelys Touya, Thomas William LeBlanc
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data. Expert review of pharmacoeconomics & outcomes research 24 (4) (2024)
Arianna Cesari, Giovanni Fabbrini, Francescaroberta Panuccio, Rachele Simeon, Anna Berardi
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review. Expert review of pharmacoeconomics & outcomes research 24 (4) (2024)
Jin-Ah Sim, Xiaolei Huang, Madeline R Horan, Justin N Baker, I-Chan Huang
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review. Expert review of pharmacoeconomics & outcomes research 24 (4) (2024)
Jorge Mestre-Ferrandiz, Marcin Czech, Josef S Smolen, Paul Cornes, Matti S Aapro, Silvio Danese, Stephen Deitch, Hannah Tyldsley, Will Foster, Pooja Shah, Mark Latymer, Arnold G Vulto
Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment. Expert review of pharmacoeconomics & outcomes research 24 (4) (2024)
Frederikke Bruun Andersen, Jakob Kjellberg, Rikke Ibsen, Catarina Sternhufvud, Birte Petersen
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study. Expert review of pharmacoeconomics & outcomes research 24 (4) (2024)

volume 24, number 5, 2024

Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, Maarten Jacobus Postma
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Cheng Ean Chee, Jasmeet Singh Khara, John Cheong, Jek Fong, Sivabalan Sivanesan, Jian Yi Choy, Meibo Hu, Amrita Viswambaram, Han Chong Toh
Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Mickaël Hiligsmann, Mitchell P DeKoven, Riddhi Doshi, Carolyn Gotay, Carlo Lazzaro, Jayashri Sankaranarayanan, Rayya Hajjar
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Abdoreza Mousavi, Ali Akbari Sari, Fakhraddin Daastari, Rajabali Daroudi
Health-related quality of life measured using the EQ-5D-3L: iranian population norms. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Janice Seinfeld, Alfredo Sobrevilla, María Laura Rosales, Mauricio Ibáñez, Delia Ruiz, Eduardo Penny, Sergio Londoño
Economic burden of type-2 diabetes in Peru: a cost-of-illness study valuing cost differences associated with the level of glycemic control. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Steven Simoens, Teresa Barcina Lacosta, Andras Inotai
Learnings from cross-border biosimilar pricing policies in Europe. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, Maarten Jacobus Postma
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Ali Jalali
Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Wei Li, Li Wan
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Shuo Kang, Jintuo Yin
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Blessing Dzingirai, Leolin Katsidzira, Vongai Mwanesani, Maarten Jacobus Postma, Marinus van Hulst, Nyashadzaishe Mafirakureva
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Wei Li, Li Wan
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Mabore Thema, Zsuzsanna Beretzky, Valentin Brodszky
Monetary valuation of one year in full capability and health based on demographics, health status, income and well-being. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Philip A Powell
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource? Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Ali Jalali
Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Akshay Shetty, Michelle Lee, Julia Valenzuela, Sammy Saab
Cost effectiveness of hepatitis C direct acting agents. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)

volume 24, number 6, 2024

Elisa Ferrer-Mallol, Clare Matthews, Rabia Aziza, Alejandro Mendoza, Navdeep Sahota, Sandra Komarzynski, Rashmi Lakshminarayana, Elin Haf Davies
Video-based assessments of activities of daily living: generating real-world evidence in pediatric rare diseases. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Katelyn R Keyloun, Jessica Abel, Julia K Garcia, Elektra J Papadopoulos, Robyn T Carson, Chad Gwaltney, Ashley F Slagle, Bill Byrom
Leveraging sensor-based functional outcomes to enhance understanding of the patient experience: challenges and opportunities. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Michel Burnier
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Bhakti Patel, Amgad N Makaryus
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Ahmad Z Al Meslamani
Barriers to digital endpoints in data collection in low and middle-income countries. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Ahmad Z Al Meslamani
The long-term clinical impact of digital endpoints and biomarkers in data collection. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Lada Leyens, John Batchelor, Erwin De Beuckelaer, Kai Langel, Bert Hartog
Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaboration. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Bhakti Patel, Amgad N Makaryus
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Ahmad Z Al Meslamani
The long-term clinical impact of digital endpoints and biomarkers in data collection. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Robert David Sandler, Lana Lai, Sophie Dawson, Sarah Cameron, Aoife Lynam, Matthew Sperrin, Zhe Hui Hoo, Martin J Wildman
Development of data processing algorithm to calculate adherence for adults with cystic fibrosis using inhaled therapy - a multi-center observational study within the CFHealthHub learning health system. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Katelyn R Keyloun, Jessica Abel, Julia K Garcia, Elektra J Papadopoulos, Robyn T Carson, Chad Gwaltney, Ashley F Slagle, Bill Byrom
Leveraging sensor-based functional outcomes to enhance understanding of the patient experience: challenges and opportunities. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Lada Leyens, John Batchelor, Erwin De Beuckelaer, Kai Langel, Bert Hartog
Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaboration. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Elisa Ferrer-Mallol, Clare Matthews, Rabia Aziza, Alejandro Mendoza, Navdeep Sahota, Sandra Komarzynski, Rashmi Lakshminarayana, Elin Haf Davies
Video-based assessments of activities of daily living: generating real-world evidence in pediatric rare diseases. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Michel Burnier
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Ahmad Z Al Meslamani
Barriers to digital endpoints in data collection in low and middle-income countries. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)
Robert David Sandler, Lana Lai, Sophie Dawson, Sarah Cameron, Aoife Lynam, Matthew Sperrin, Zhe Hui Hoo, Martin J Wildman
Development of data processing algorithm to calculate adherence for adults with cystic fibrosis using inhaled therapy - a multi-center observational study within the CFHealthHub learning health system. Expert review of pharmacoeconomics & outcomes research 24 (6) (2024)

volume 24, number 7, 2024

Jessica Q Duong, Ryan F Bloomquist, Steven R Feldman
How can physicians improve medication adherence and outcomes in dermatological conditions? Expert review of pharmacoeconomics & outcomes research 24 (7) (2024)
Dalma Hosszú, Alexandra L Dima, Francisca Leiva Fernández, Marie Paule Schneider, Liset van Dijk, Krisztina Tóth, Mark Duman, Wendy Davis, Cristian Andriciuc, Rebecca Egan, Bernard Vrijens, Przemyslaw Kardas, Noemi Bitterman, Iva Mucalo, Cristina Mihaela Ghiciuc, Tamás Ágh
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study. Expert review of pharmacoeconomics & outcomes research 24 (7) (2024)
Katrina S Firlik, Vamshi Ruthwik Anupindi, Vincent Hayes, Mitchell DeKoven, Asif Shaikh, Jessica Franchino-Elder
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program. Expert review of pharmacoeconomics & outcomes research 24 (7) (2024)
Nannan Li, Niklas Rye Jørgensen, Jean-Yves Reginster, Mickaël Hiligsmann
The impact of bone turnover marker on medication adherence and the health economics-related consequences. Expert review of pharmacoeconomics & outcomes research 24 (7) (2024)
Tamás Ágh, Mickaël Hiligsmann
Bridging the gap: enhancing medication adherence through research and innovation. Expert review of pharmacoeconomics & outcomes research 24 (7) (2024)
Ahmad Z Al Meslamani
Policy solutions for medication non-adherence: what can governments do? Expert review of pharmacoeconomics & outcomes research 24 (7) (2024)
Siraj Al-Obaidi, Rima Hijazeen, Rasha M Arabyat, Ibrahim Alabbadi
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients' characteristics and out-of-pocket payments. Expert review of pharmacoeconomics & outcomes research 24 (7) (2024)
Sinaa Al-Aqeel
Nonadherence to antiseizure medications: what have we learned and what can be done next? Expert review of pharmacoeconomics & outcomes research 24 (7) (2024)
Ahmad Z Al Meslamani, Nannan Li
Assessing the economic impact of digital endpoints on medication adherence. Expert review of pharmacoeconomics & outcomes research 24 (7) (2024)
André Pascal Kengne, Jean-Baptiste Brière, Irene Asensio Gudiña, Xiaobin Jiang, Petya Kodjamanova, Liga Bennetts, Zeba M Khan
The impact of non-pharmacological interventions on adherence to medication and persistence in dyslipidaemia and hypertension: a systematic review. Expert review of pharmacoeconomics & outcomes research 24 (7) (2024)